Know Cancer

or
forgot password

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Venous Thromboembolism

Thank you

Trial Information

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer


Inclusion Criteria:



- Subjects must provide informed consent

- Men or women aged 18 years or more

- Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low
Molecular Weight Heparin before entry into the study

Exclusion Criteria:

- Contraindication to the use of Low Molecular Weight Heparin

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Prescription conditions and use of Low Molecular Weight Heparin in the French usual practice for the treatment of symptomatic Venous Thromboembolism in patients with cancer at up to 6 months

Outcome Time Frame:

up to 6 months

Safety Issue:

No

Principal Investigator

Dominique Farge Bancel, Pr

Investigator Role:

Principal Investigator

Investigator Affiliation:

Groupe Francophone Thrombose et Cancer

Authority:

France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé

Study ID:

Tropique

NCT ID:

NCT01803022

Start Date:

November 2012

Completion Date:

June 2014

Related Keywords:

  • Venous Thromboembolism
  • Venous Thromboembolism
  • Cancer
  • Low Molecular Weight Heparin
  • Thromboembolism
  • Venous Thromboembolism
  • Venous Thrombosis

Name

Location